Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Ahmed Sawas, MD, Constance Lau, MPH, Michael Thomson, MS, Kathleen Maignan, NP, MSN

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-141274

Published: 2020

Journal Articles

Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Pei-Hsuan Chen, Mikel Lipschitz, M.S., Scott Rodig, MD PhD, George Vlad

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140096

Published: 2020

Journal Articles

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Blood (2020) 136 (Supplement 1): 41–43.

https://doi.org/10.1182/blood-2020-136198

Published: 2020

Journal Articles

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Francesca Montanari, MD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Jennifer Kimberly Lue, MD, Enrica Marchi, MD, PhD, Dejan Radeski, MBBS, FRACP, FRCPA, Bin Cheng, PhD, Govind Bhagat, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 2909.

https://doi.org/10.1182/blood-2019-131841

Published: 2019

Journal Articles

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Ahmed Sawas, MD, Helen Ma, MD, Andrei Shustov, MD, Pamela Hsu, MS, Gajanan Bhat, Mark Acosta, PharmD, Steven M. Horwitz, MD, Owen A. O'Connor, MD PhD

Blood (2019) 134 (Supplement_1): 4050.

https://doi.org/10.1182/blood-2019-127155

Published: 2019

Journal Articles

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Francesca Montanari, MD, Enrica Marchi, MD, PhD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 1002.

https://doi.org/10.1182/blood-2018-99-116605

Published: 2018

Journal Articles

Atypical Immunophenotype Predicts Worse Prognosis in Adult T-Cell Lymphoma/Leukemia: A Retrospective Study of 63 Caribbean Patients at a New York City Tertiary Center

Bachar Samra, MD, Edwin Chiu, MD, Bo Lin, MD PhD, Eric Tam, MD BS, Babak Baseri, MD MS, Iuliana Shapira, MD, Jason Gonsky, MD PhD, Robert David Lewis, MD, Gurinder Sidhu, MD, Ahmed Sawas, MD, Evelyn O. Taiwo, MD

Blood (2018) 132 (Supplement 1): 2906.

https://doi.org/10.1182/blood-2018-99-111208

Published: 2018

Journal Articles

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Ahmed Sawas, MD, John Kuruvilla, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Francesca Montanari, MD, Kerry J Savage, BSc, MD MSc, Hager Elgedawe, Diego Villa, MD, Michael Crump, MD, Joseph M Connors, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2907.

https://doi.org/10.1182/blood-2018-99-117251

Published: 2018

Journal Articles

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Ahmed Sawas, MD, Hager Elgedawe, George Vlad, PhD, Mikel Lipschitz, M.S., Pei-Hsuan Chen, PhD, Scott J Rodig, MD, Jennifer Kimberly Lue, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Maher Abdul Hay, MD, Karen Khan, BSN, Laine E. Atkins, RN, Aishling M. Rada, RN, Larisa Geskin, MD, Owen A. O'Connor, MD, PhD

Blood (2018) 132 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2018-99-115269

Published: 2018

Journal Articles

Safety of Intrathecal Liposomal Cytarabine Given with Intrathecal Hydrocortisone, with or without Systemic Steroids

Jessica Baron, PharmD, Lorenzo Falchi, MD, Ahmed Sawas, MD

Blood (2017) 130 (Supplement 1): 5219.

https://doi.org/10.1182/blood.V130.Suppl_1.5219.5219

Published: 2017

Journal Articles

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

Lorenzo Falchi, MD, Jennifer Kimberly Lue, MD, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Enrica Marchi, MD, PhD, Emily Lichtenstein, RN, Karen Khan, BSN, Hyea Kim, NP-BC, Laine E. Atkins, RN, Aishling M. Rada, RN, Celeste Rojas, Cremers Serge, PhD PharmD, Owen A. O'Connor, MD, PhD

Blood (2017) 130 (Supplement 1): 1515.

https://doi.org/10.1182/blood.V130.Suppl_1.1515.1515

Published: 2017

Journal Articles

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

Jennifer E Amengual, MD, Renee Lichtenstein, Celeste Rojas, Ahmed Sawas, MD, Changchun Deng, MD PhD, Emily Lichtenstien, Karen Kahn, Jennifer Kimberly Lue, MD, Yuxuan Liu, PhD, Changhong Qiao, Renu Nandakumar, PhD, Serge Cremers, PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 1824.

https://doi.org/10.1182/blood.V128.22.1824.1824

Published: 2016

Journal Articles

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses

Lorenzo Falchi, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Emily Lichtenstein, RN, Karen Khan, BSN, Lawrence H. Schwartz, MD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 2999.

https://doi.org/10.1182/blood.V128.22.2999.2999

Published: 2016

Journal Articles

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival

Blood (2016) 128 (22): 4159.

https://doi.org/10.1182/blood.V128.22.4159.4159

Published: 2016

Journal Articles

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Ahmed Sawas, MD, Joseph M. Connors, MD, John G. Kuruvilla, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Diego Villa, MDMPH, Michael Crump, MD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 586.

https://doi.org/10.1182/blood.V126.23.586.586

Published: 2015

Journal Articles

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Jennifer E Amengual, MD, Lichtenstein Renee, Celeste Rojas, Kelly Zullo, MS, Maximilian Lombardo, Emily Lichtenstein, RN, Ellen Neylon, NP, Changchun Deng, MD PhD, Ahmed Sawas, MD, Bijal D Shah, Catherine Wheeler, MD, Simon S Jones, PhD, Owen A. O'Connor, MD PhD

Blood (2015) 126 (23): 1280.

https://doi.org/10.1182/blood.V126.23.1280.1280

Published: 2015

Journal Articles

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

Owen A. O'Connor, MD PhD, Kelly Zullo, MS, Enrica Marchi, MD PhD, Changchun Deng, MD PhD, Ahmed Sawas, MD, Donald Steven Colbourn, MD, Celeste Rojas, Renee Lichtenstein, Ellen Neylon, NP, Emily Lichtenstein, RN, Michael Smith, RN, Luigi Scotto, PhD, Jennifer E Amengual, MD

Blood (2015) 126 (23): 1282.

https://doi.org/10.1182/blood.V126.23.1282.1282

Published: 2015

Journal Articles

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Ahmed Sawas, MD, Kerry J. Savage, MDMSc, Raymond Perez, MD, Ranjana H Advani, MD, Anna Butturini, MD, Jacqueline Lackey, Fabio Trave, MD, Banmeet Anand, PhD, Yao Huang, Leonard Reyno, MD, Owen A. O'Connor, MD

Blood (2015) 126 (23): 3976.

https://doi.org/10.1182/blood.V126.23.3976.3976

Published: 2015

Journal Articles

The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)

Dejan Radeski, MBBS,FRACP,FRCPA, Daniela Hoehn, MD PhD, Francesca Montanari, MD, Bachir Alobeid, MD, Yuan Zhang, MS MA, Jennifer E Amengual, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Owen A. O'Connor, MD PhD, Govind Bhagat, MD

Blood (2014) 124 (21): 4449.

https://doi.org/10.1182/blood.V124.21.4449.4449

Published: 2014

Journal Articles

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Ann LaCasce, MD, R. Gregory Bociek, MD, Jeffrey Matous, MD, Ahmed Sawas, MD, Paolo Caimi, MD, Stephen M. Ansell, MD PhD, Miguel Islas-Ohlmayer, MD, Eric Cheung, MD, Edward Agura, MD, Caroline Behler, MD, Howland Crosswell, MD, Julie M. Vose, MD MBA, Neil Josephson, MD, Ranjana Advani, MD

Blood (2014) 124 (21): 293.

https://doi.org/10.1182/blood.V124.21.293.293

Published: 2014

NARROW

Real-World Outcomes of Patients with Diffuse Large B-Cell Lymphoma Receiving Second Line Therapy in the United States

Title: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Updates from Ongoing, First-in-Human Phase 1 Dose Escalation and Expansion Study of TTI-621, a Novel Biologic Targeting CD47, in Patients with Relapsed or Refractory Hematologic Malignancies

Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype

Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)

Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL)

Atypical Immunophenotype Predicts Worse Prognosis in Adult T-Cell Lymphoma/Leukemia: A Retrospective Study of 63 Caribbean Patients at a New York City Tertiary Center

Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202)

Safety of Intrathecal Liposomal Cytarabine Given with Intrathecal Hydrocortisone, with or without Systemic Steroids

A Phase 1/2 Study of Oral 5-Azacitidine and Romidepsin in Patients with Lymphoid Malignancies Reveals Promising Activity in Heavily Pretreated Peripheral T-Cell Lymphoma (PTCL)

The Pralatrexate - Romidepsin Doublet: A Well Tolerated and Highly Effective Combination for Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses

A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator's Choice in the Treatment of Patients with Relapsed/Refractory Adult T-Cell Leukemia-Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival

The Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) Demonstrates Marked Activity in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) and Anaplastic Large T-Cell Lymphoma (ALCL): Results of an International Multi Center Phase I/II Experience

Translational Focus on Targeting HDAC6 with Ricolinostat Confirms Potent Activity in Preclinical Models of Lymphoma and a Favorable Toxicity Profile in Patients with Relapsed or Refractory Lymphoma

Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma)

Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only